INTRODUCTION
Bronchial asthma is a common chronic inflammatory disease of the airways in which the episodic acute limitation of airflow results in symptoms such as wheezing, coughing chest tightness and shortness of breath. 1 In 2011, 235-300 million people were diagnosed globally with asthma and it caused 2,50,000 deaths. [2] [3] [4] Asthma is responsible for significant morbidity worldwide. It is the 25 th leading cause of disability adjusted life years lost per year. Asthma accounts for 1 of 250 deaths worldwide, however most of these deaths are preventable with appropriate management. 5, 6 The treatment of asthma has largely revolved around the beta adrenergic agonists and corticosteroids given by the inhalational route using a metered dose inhaler. While these drugs do cause relief of symptoms, there are a substantial proportion of patients who continue to exhibit persistent symptoms inspite of being on these medication at maximal doses. 7 Leukotriene antagonists have been a suitable choice only in those with mild persistent asthma and exercise induced asthma. Omalizumab, the first ever monoclonal antibody for asthma, is associated with anaphylactic reactions and neoplasms have occurred in clinical trials. 8 The search for a better drug to target the symptoms and the disease pathophysiology of asthma has taken researchers to explore various therapeutic targets in search of the elusive molecule. One of the fruits of this extensive search has been the discovery of a monoclonal antibody named mepolizumab that was approved by the two major drug regulators, the US FDA and the EMA. We have described in brief the mechanism of action, efficacy, safety, pharmacokinetics, regulatory history of mepolizumab in this review.
Mechanism of action
Mepolizumab is a humanized IgG1 monoclonal antibody. Although the exact mechanism of action of mepolizumab is unknown, the drug is known to bind to interleukin-5 and prevent its interaction with the alpha chain of the interleukin-5 receptor complex. IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils, which are involved in the inflammatory cascade of asthma. Patients with eosinophilic variant of asthma have a high proportion of eosinophil content in the sputum, blood and bone marrow. The eosinophils are associated with the airway hyperresponsiveness and inflammation in these patients. Mepolizumab by virtue of its binding potential to the IL-5 is able to neutralize the eosinophilic inflammation in the lungs and thus prevent disease exacerbation.
Efficacy
Clinical Trials DREAM STUDY: The DREAM study was the largest ever double blind placebo controlled trial that evaluated the effect of mepolizumab in severe eosnophilic asthma. Pavord et al 9 Patients were assigned to 4 groups (1:1:1:1) namely mepolizumab in doses of 75 mg (n=154), 250 mg (n=152) and 750 mg (n=156) or placebo (n=159). Compared with placebo group, mepolizumab was found to reduce the number of exacerbations in the study period irrespective of the dose used. There was also a delay in the time to first episode of exacerbation, number of exacerbations requiring emergency visit to hospital. It also showed a reduction in the blood eosinophil and sputum count. The efficacy of mepolizumab was found to be influenced by blood eosinophil count and the number of exacerbations in the preceding year (Table 1) .
In a single-center, randomized, double blind, placebo-controlled, parallel-group clinical trial in patients with refractory eosinophilic asthma, patients were assigned to receive 12 infusions of either 750 mg of mepolizumab delivered intravenously (n=29) or matched placebo (150 
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The ability of mepolizumab to reduce the corticosteroid requirement was assessed in a randomized, double-blind trial involving 135 patients with severe eosinophilic asthma. 11 As compared with placebo, there was 2.39 times greater likelihood of the reduction in glucocorticoid dosing among mepolizumab users. The patients who were in the mepolizumab arm showed a 50% median dose reduction. Inspite of the reduction in steroid dosing among mepolizumab users, they had a lower annual rate of exacerbations (1.44 vs. 2.12, P=0.04) and a lower symptom score (P=0.004).
Safety
The most common adverse events are headache (21%), nasopharyngitis (22%), Hypersensitivity (1%), chest pain (3%), facial flushing (7%), erectile or ejaculatory dysfunction (7%), rash (7%), pruritus (7%), fatigue (7%), systemic reactions, local injection site reactions.
9-11
Pharmacokinetics
Mepolizumab is given via subcutaneous injection at a dosing range of 12.5 to 250 mg once every four weeks. The bioavailability of mepolizumab was estimated to be approximately 80% and the mean terminal half-life (t 1/2 ) ranged from 16 to 22 days. The central volume of distribution of mepolizumab in patients with asthma is estimated to be 3.6 L for a 70-kg individual.
Precautions
Mepolizumab should not be administered to patients with a history of hypersensitivity or acute exacerbations, acute bronchospasm or status asthmaticus. Clinical trials have not been conducted to investigate the effect of renal impairment and hepatic impairment.
Current Status of the Mepolizumab
Mepolizumab was approved by EMA and US FDA in 2015 for the treatment of severe eosinophilic asthma. 12 Mepolizumab is under clinical trials for the treatment of atopic dermatitis, hypereosinophilic syndrome, eosinophilic esophagitis, nasal polyposis, eosinophilic granulomatosis with polyangiitis (i.e., Churg Strauss syndrome), and chronic obstructive pulmonary disease. [13] [14] [15] [16] [17] The drug should ideally be prescribed in patients with the eosinophilic variant of asthma who are poor responders to even systemic corticosteroids. The drug is expected to cost between 10,000 to 15,000 US dollars per year which only adds to the economic burden, but considering the history of drug pricing with monoclonal antibodies, this is least surprising.
